Weighted Average Number of Shares Outstanding, Diluted of Ultragenyx Pharmaceutical Inc. from 31 Mar 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Ultragenyx Pharmaceutical Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Mar 2017 to 31 Dec 2025.
  • Ultragenyx Pharmaceutical Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 31 Dec 2025 was 98,600,000, a 9% increase year-over-year.
  • Ultragenyx Pharmaceutical Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2025 was 98,600,000, a 9% increase from 2024.
  • Ultragenyx Pharmaceutical Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 90,500,000, a 23% increase from 2023.
  • Ultragenyx Pharmaceutical Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 73,500,000, a 5.1% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Ultragenyx Pharmaceutical Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 98,600,000 +8,100,000 +9% 01 Oct 2025 31 Dec 2025 10-K 18 Feb 2026 2025 FY
Q3 2025 99,771,297 +4,277,301 +4.5% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 98,460,445 +11,879,929 +14% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 96,288,650 +12,002,358 +14% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 90,500,000 +17,000,000 +23% 01 Oct 2024 31 Dec 2024 10-K 18 Feb 2026 2025 FY
Q3 2024 95,493,996 +23,829,503 +33% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 86,580,516 +15,682,525 +22% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 84,286,292 +13,917,814 +20% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 73,500,000 +3,585,775 +5.1% 01 Oct 2023 31 Dec 2023 10-K 18 Feb 2026 2025 FY
Q3 2023 71,664,493 +1,610,320 +2.3% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 70,897,991 +972,633 +1.4% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2024 2024 Q2
Q1 2023 70,368,478 +851,810 +1.2% 01 Jan 2023 31 Mar 2023 10-Q 03 May 2024 2024 Q1
Q4 2022 69,914,225 01 Oct 2022 31 Dec 2022 10-K 19 Feb 2025 2024 FY
Q3 2022 70,054,173 +2,178,810 +3.2% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 69,925,358 +2,317,606 +3.4% 01 Apr 2022 30 Jun 2022 10-Q 04 Aug 2023 2023 Q2
Q1 2022 69,516,668 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q3 2021 67,875,363 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 67,607,752 +6,461,521 +11% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2021 2021 Q2
Q2 2020 61,146,231 +3,626,923 +6.3% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q2 2019 57,519,308 01 Apr 2019 30 Jun 2019 10-Q 30 Jul 2020 2020 Q2
Q1 2019 53,209,215 +4,131,473 +8.4% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2019 2019 Q1
Q1 2018 49,077,742 +7,236,130 +17% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q1 2017 41,841,612 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1

Ultragenyx Pharmaceutical Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 98,600,000 +8,100,000 +9% 01 Jan 2025 31 Dec 2025 10-K 18 Feb 2026 2025 FY
2024 90,500,000 +17,000,000 +23% 01 Jan 2024 31 Dec 2024 10-K 18 Feb 2026 2025 FY
2023 73,500,000 +3,585,775 +5.1% 01 Jan 2023 31 Dec 2023 10-K 18 Feb 2026 2025 FY
2022 69,914,225 +2,118,685 +3.1% 01 Jan 2022 31 Dec 2022 10-K 19 Feb 2025 2024 FY
2021 67,795,540 +6,949,990 +11% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
2020 60,845,550 01 Jan 2020 31 Dec 2020 10-K 17 Feb 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.